{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T03:58:14Z","timestamp":1648958294745},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00105-011-2195-9","type":"journal-article","created":{"date-parts":[[2012,1,2]],"date-time":"2012-01-02T13:52:07Z","timestamp":1325512327000},"page":"10-15","source":"Crossref","is-referenced-by-count":2,"title":["HIV-Infektion"],"prefix":"10.1007","volume":"63","author":[{"given":"A.","family":"Potthoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Rasokat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.H.","family":"Brockmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,1,4]]},"reference":[{"key":"2195_CR1","first-page":"CD009153","volume":"8","author":"Anglemyer","year":"2011","unstructured":"Anglemyer A, Rutherford GW, Baggaley RC et al (2011) Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 8:CD009153","journal-title":"Cochrane Database Syst Rev"},{"key":"2195_CR2","doi-asserted-by":"crossref","unstructured":"Arast\u00e9h K (2010) 24\u00a0Wk efficacy and safety of transitioning virologically stable HIV-1\u00a0patients from IR nevirapine 200\u00a0mg BID to nevirapine XR 400\u00a0mg Q. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, MA, USA, September 12\u201315 (Poster:207)","DOI":"10.1186\/1758-2652-13-S4-P45"},{"key":"2195_CR3","unstructured":"Clinical Trial gov. Strategic Timing of Antiretroviral Treatment (START). http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00867048"},{"key":"2195_CR4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","volume":"378","author":"Cohen","year":"2011","unstructured":"Cohen CJ, Andrade-Villanueva J, Clotet B et al (2011) Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 378:229\u2013237","journal-title":"Lancet"},{"key":"2195_CR5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","volume":"365","author":"Cohen","year":"2011","unstructured":"Cohen MS, Chen YQ, Mc Cauly M et al (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365:493\u2013505","journal-title":"N Engl J Med"},{"key":"2195_CR6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","volume":"51","author":"Cooper","year":"2010","unstructured":"Cooper RD, Wiebe N, Smith N et al (2010) Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51(5):496\u2013505","journal-title":"Clin Infect Dis"},{"key":"2195_CR7","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","volume":"371","author":"DAD","year":"2008","unstructured":"DAD Study Group, Sabin CA, Worm SW et al (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the DAD study: a multi-cohort collaboration. Lancet 371:1417\u20131426","journal-title":"Lancet"},{"key":"2195_CR8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/cid\/ciq068","volume":"52","author":"Delaney","year":"2011","unstructured":"Delaney KP, Branson BM, Uniyal A et al (2011) Evaluation of the performance characteristics of 6 rapid HIV antibody tests. Clin Infect Dis 52:257\u2013263","journal-title":"Clin Infect Dis"},{"key":"2195_CR9","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.2165\/11203800-000000000-00000","volume":"70","author":"Deeks","year":"2010","unstructured":"Deeks ED, Perry CM (2010) Efavirenz\/emtricitabine\/tenofovir disoproxil fumarate single-tablet regimen (Atripla\u00ae): a review of its use in the management of HIV infection. Drugs 70:2315\u20132338","journal-title":"Drugs"},{"key":"2195_CR10","unstructured":"Deutsch-\u00d6sterreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion (Stand M\u00e4rz 2010). http:\/\/www.daignet.de"},{"key":"2195_CR11","unstructured":"Ding X, Andraca-Carrera E, Cooper C et al (2011) No association of myocardial infarction with ABC use: an FDA Meta-analysis18th CROI 2011, Boston, Poster 808"},{"key":"2195_CR12","unstructured":"EACS Guidelines: Clinical management and treatment of HIV-infected adults in Europe. http:\/\/www.europeanaidsclinicalsociety.org\/images\/stories\/EACS-pdf\/1_treatment_of_hiv_infected_adults.pdf"},{"key":"2195_CR13","unstructured":"Efficacy and safety of GSK biologicals HIV vaccine in antiretroviral therapy (ART)-naive HIV-1 infected persons. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01218113"},{"key":"2195_CR14","unstructured":"Elion R (2010) The single-tablet regimen of elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate (EVG\/COBI\/FTC\/TDF; Quad) maintains a high rate of virologic suppression, and cobicistat (COBI) is an effective pharmacoenhancer through 48\u00a0weeks ICAAC 2010; Abstract H-938b"},{"key":"2195_CR15","unstructured":"Gathe J (2010) Comparison of 48\u00a0week efficacy and safety of 400\u00a0mg QD nevirapine extended release formulation (Viramune XR) versus 200\u00a0mg BID nevirapine immediate release formulation (Viramune IR) in combination with Truvada in antiretroviral (ARV) naive HIV-1 infected patients (VERxVE). XVIII International AIDS Conference, Vienna, Austria; July 18\u201323, 2010 oral presentation"},{"key":"2195_CR16","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/QAI.0b013e31817efb54","volume":"48","author":"Lewden","year":"2008","unstructured":"Lewden C, May T, Rosenthal E (2008) Changes in causes of death among adults infected by hiv between 2000 and 2005: the \u201eMortalit\u00e9 2000 and 2005\u201c Surveys (ANRS EN 19 and Mortavic). J Acquir Immune Defic Syndr 48:590\u2013598","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2195_CR17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","volume":"358","author":"Mallal","year":"2008","unstructured":"Mallal S, Phillips E, Carosi G et al (2008) PREDICT-1 study team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568\u2013579","journal-title":"N Engl J Med"},{"key":"2195_CR18","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0b013e32832d7350","volume":"23","author":"Mills","year":"2009","unstructured":"Mills AM, Nelson M, Jayaweera D et al (2009) Once-daily darunavir\/ritonavir vs. lopinavir\/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. Aids 23:1679\u20131688","journal-title":"Aids"},{"key":"2195_CR19","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/S0140-6736(08)61081-8","volume":"372","author":"Molina","year":"2008","unstructured":"Molina JM, Andrade-Villanueva J, Echevarria J et al (2008) Once daily atazanavir\/ritonavir versus twice-daily lopinavir\/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48\u00a0week efficacy and safety results of the CASTLE study. Lancet 372:646\u2013655","journal-title":"Lancet"},{"key":"2195_CR20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","volume":"378","author":"Molina","year":"2011","unstructured":"Molina JM, Cahn P, Grinsztejn B et al (2011) Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 378:238\u2013246","journal-title":"Lancet"},{"key":"2195_CR21","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archpediatrics.2010.161","volume":"164","author":"Mullins","year":"2010","unstructured":"Mullins TL, Kollar LM, Lehmann C, Kahn JA (2010) Changes in human immunodeficiency virus testing rates among urban adolescents after introduction of routine and rapid testing. Arch Pediatr Adolesc Med 164(9):870\u2013874","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2195_CR22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.qai.0000245886.51262.67","volume":"43","author":"Pozniak","year":"2006","unstructured":"Pozniak AL, Gallant JE, DeJesus E et al (2006) Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine\/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes \u2013 a 96-week analysis. J Acquir Immune Defic Syndr 43(5):535\u2013540","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2195_CR23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1310\/hct1002-76","volume":"10","author":"Pulido","year":"2009","unstructured":"Pulido F, Estrada V, Baril JG et al (2009) Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir\/ritonavir in combination with abacavir\/lamivudine over 144\u00a0weeks. HIV Clin Trials 10:76\u201387","journal-title":"HIV Clin Trials"},{"key":"2195_CR24","unstructured":"Qualit\u00e4tssicherungsvereinbarung HIV\/AIDS. http:\/\/www.kbv.de\/23945.html"},{"key":"2195_CR25","first-page":"179","volume":"21","author":"RKI","year":"2011","unstructured":"RKI (2011) HIV Infektionen und AIDS-Erkrankungen in Deutschland. Epidemiol Bull 21:179\u2013198","journal-title":"Epidemiol Bull"},{"key":"2195_CR26","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)16385-X","volume":"363","author":"Robinson","year":"2004","unstructured":"Robinson P, Wit FW, Lange JM (2004) 2NN study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 363:1253\u20131263","journal-title":"Lancet"},{"key":"2195_CR27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/cid\/cir510","volume":"53","author":"Rockstroh","year":"2011","unstructured":"Rockstroh JK, Lennox JL, Dejesus E et al (2011) Long-term treatment with raltegravir or efavirenz combined with tenofovir\/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 53:807\u2013816","journal-title":"Clin Infect Dis"},{"key":"2195_CR28","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/QAD.0b013e32832cbcc2","volume":"23","author":"Smith","year":"2009","unstructured":"Smith KY, Patel P, Fine D et al (2009) Randomized, double-blind, placebo-matched, multicenter trial of abacavir\/lamivudine or tenofovir\/emtricitabine with lopinavir\/ritonavir for initial HIV treatment. AIDS 23:1547\u20131556","journal-title":"AIDS"},{"key":"2195_CR29","first-page":"shorter","volume":"5202","author":"Sax","year":"2008","unstructured":"Sax P, Tierney C, Collier A (2008). ACTG 5202: shorter time to virologic failure with ABC\/3TC than TDF\/FTC in treatment-naive subjects with HIV RNA >\u2009100,000. XVII International AIDS Conference. August 3\u20138 Mexico City (Abstract THAB0303)","journal-title":"ACTG"},{"key":"2195_CR30","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1097\/QAD.0b013e32833c3281","volume":"24","author":"Welz","year":"2010","unstructured":"Welz T, Childs K, Ibrahim F et al (2010) Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 24:1923\u20131928","journal-title":"AIDS"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-011-2195-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-011-2195-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-011-2195-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T02:32:33Z","timestamp":1640313153000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-011-2195-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["2195"],"URL":"https:\/\/doi.org\/10.1007\/s00105-011-2195-9","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}